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Clindamycin resistance in Staphylococcus species can be
either constitutive or inducible. Inducible resistance cannot be
detected by the conventional antimicrobial susceptibility test.
In this study, we determined the prevalence of inducible
clindamycin resistance in staphylococcal isolates at a Korean
tertiary care hospital. Between February and September 2004,
1,519 isolates of Staphylococcus aureus and 1,043 isolates of
coagulase-negative staphylococci (CNS) were tested for in-
ducible resistance by the D-zone test. Overall, 17% of MRSA,
84% of MSSA, 37% of MRCNS, and 70% of MSCNS were
susceptible to clindamycin. Of the erythromycin non-sus-
ceptible, clindamycin-susceptible isolates, 32% of MRSA,
35% of MSSA, 90% of MRCNS, and 94% of MSCNS had
inducible clindamycin resistance. Inducible clindamycin resis-
tance in staphylococci was highly prevalent in Korea. This
study indicates importance of the D-zone test in detecting
inducible clindamycin resistance in staphylococci to aid in the
optimal treatment of patients.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
is a notorious nosocomial pathogen prevalent in
many countries. A study by the Korean Nation-
wide Surveillance of Antimicrobial Resistance
(KONSAR) program showed that 68% of S. aureus
isolates in 2003 were methicillin-resistant.
1 Vanco-
mycin has been used increasingly to treat MRSA
infections. Dissemination of vancomycin-resistant
enterococci was considered to be partly due to
increased vancomycin use. Rapid increase in
vancomycin resistance necessitates the restriction
of vancomycin usage, as well as encourages treat-
ment with older antimicrobial agents, such as
trimethoprim-sulfamethoxazole and clindamycin.
Clindamycin, a lincosamide antibiotic active
against gram-positive microorganisms including
staphylococci and streptococci, inhibits bacterial
protein synthesis. It can be administered orally to
treat mild infections in children or soft tissue
infections.
2-4 The clindamycin resistance mech-
anism is primarily due to ribosomal modification
by methylases encoded by erm genes. Methylation
of 23S rRNA decreases the affinity for clinda-
mycin, all macrolides, and type B streptogramins
(the MLSB phenotype).
5 Some of the enzymes are
constitutively regulated, while others are in-
ducibly regulated by translational attenuation of a
mRNA leader sequence. In the absence of erythro-
mycin, the mRNA is in an inactive conformation
due to a sequestered Shine-Dalgarno sequence,
preventing the efficient initiation of translation of
erm transcripts.
6
Constitutive resistance can be readily detected,
but inducible resistance is not detectable by
routine antimicrobial susceptibility tests.
7,8 The
Clinical and Laboratory Standards Institute (CLSI)
recommends testing for inducible clindamycin
resistance in isolates of staphylococci by using a
D-zone test.
9 This test is important for optimal
treatment of patients, but the prevalence of in-
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ducible clindamycin resistance has not yet been
reported in Korea. Aim of this study was to deter-
mine the prevalence of inducible clindamycin
resistance in S. aureus and coagulase-negative
staphylococci (CNS) isolated from patients in a
tertiary care hospital in Korea.
MATERIALS AND METHODS
Between February and September 2004, non-
duplicate S. aureus and CNS were isolated from
patients in a tertiary care university hospital in
Korea. The species were identified by conventio-
nal methods using a coagulase tube, mannitol-salt
agar, and DNase agar or by using the Vitek GPI
card system (bioMerieux, Marcy l'Etoile, France).
Antimicrobial susceptibilities were determined by
the CLSI disk diffusion method.
9 To detect
inducible clindamycin resistance, the D-zone test
was performed. A staphylococcal suspension
equivalent to 0.5 McFarland turbidity was used to
inoculate a Mueller-Hinton agar (MHA) plate.
Then, 2- g μ clindamycin and 15- g erythromycin μ
disks (Becton- Dickinson Microbiology Systems,
Cockeysville, MA, USA) were placed 15 mm apart
(margin to margin).
10 After an 18-hour incubation
at 35 , a D shaped blunting of the clindamycin
disk inhibition zone adjacent to the erythromycin
disk was interpreted as positive.
RESULTS
Overall, the antimicrobial resistance rates of S.
aureus and CNS in 2004 at the tertiary care hos-
pital were 59% and 54% to oxacillin (data not
shown). The resistance rates of MRSA and methi-
cillin-susceptible Staphylococcus aureus (MSSA)
were as follows: 77% and 4% to clindamycin, 90%
and 26% to erythromycin, 22% and 1% to cotri-
moxazole, 66% and 14% to tetracycline, and 84%
and 10% to fluoroquinolone, respectively. Resis-
tance rates of CNS are shown in Table 1.
The percentages of strains with constitutive and
inducible clindamycin resistance were as follows:
79% and 4% of MRSA, 6% and 9% of MSSA, 33%
and 30% of MRCNS, and 9% and 21% of methi-
cillin-susceptible coagulase-negative staphylococci
(MSCNS), respectively (Table 2). Of the erythro-
mycin non-susceptible but clindamycin-suscep-
tible isolates, 32% of MRSA, 35% of MSSA, 90%
of MRCNS, and 94% of MSCNS were inducibly
clindamycin resistant.
DISCUSSION
In the present study, the resistance rates of
methicillin-susceptible staphylococci to clinda-
mycin, erythromycin, tetracycline, and fluoroqui-
nolone were much lower than those of methi-
cillin-resistant isolates. However, in general,
tetracyclines and fluoroquinolones are not recom-
mended for the treatment of pediatric patients and
pregnant women because of possible side effects.
It is noteworthy that clindamycin susceptible rates
were higher than those of erythromycin, regard-
less of methicillin susceptibility.
Clindamycin is indicated for the treatment of
soft tissue infections, pediatric infections caused
by staphylococci, or for patients allergic to - β
lactam agents.
2-4 Inducible clindamycin-resistant
staphylococci show susceptible results in conven-
tional susceptibility tests, but can be converted to
a constitutively resistant phenotype during clinda-
mycin treatment.
11,12 As the resistance conversion
may result in clindamycin treatment failure,
13,14
detection of inducible clindamycin resistance is
necessary.
9 Inducible clindamycin resistance can
be detected only by the D-zone test.
7,8 When a
D-zone test shows a distorted zone of inhibition
around a clindamycin disk by erythromycin, the
isolate is considered to be inducible clindamycin
resistance.
Possible variations in the prevalence of consti-
tutive and inducible clindamycin resistance have
been reported depending on regional and bac-
terial species.
11,14,15 In our study, the rate of indu-
cible clindamycin resistance in erythromycin non-
susceptible and clindamycin-susceptible staphylo-
coccal isolates was 63% (data not shown); this was
similar to 62% in Iowa
11 and 56% in Maryland
14
in the USA. Schreckenberger reported that in-
ducible clindamycin resistance was more pre-
valent in MRSA.
15 However, in our study; in-
ducibly clindamycin-resistant strains were more
prevalent in CNS (91%) than in MRSA (32%). OurHwan Sub Lim, et al.
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data indicate that if the D-zone test is not per-
formed, 32% of MRSA, 35% of MSSA, 90% of
MRCNS, and 94% of MSCNS isolates with an
erythromycin non-susceptible and clindamycin-
susceptible pattern are mistakenly interpreted as
clindamycin susceptible, possibly resulting in
treatment failure.
Almer reported that inducible clindamycin
resistance in CA-MRSA was relatively prevalent
(28%).
16 In this study, there were no significant
differences between inpatient and outpatient
incidences of inducible clindamycin resistance of
staphylococci, except for MRSA. The higher pre-
valence of inducible clindamycin resistance in
outpatient isolated MRSA is not clear, but it is
possible that the isolates are, in reality, hospital-
associated strains.
In summary, 32-35% of erythromycin non-sus-
ceptible and clindamycin-susceptible S. aureus and
90-94% of erythromycin non-susceptible and
clindamycin-susceptible CNS showed inducible
resistance to clindamycin. This study indicates the
Table 1. Antimicrobial Susceptibility of Staphylococci Isolated between February and September 2004
Organism (No. tested)/Antimicrobial agents
Susceptibility (%)
Susceptible Intermediate Resistant
Methicillin-resistant S. aureus (888)
Clindamycin 21 2 77
Erythromycin 8 2 90
Trimethoprim-sulfamethoxazole 77 1 22
Tetracycline 33 1 66
Fluoroquinolone 8 8 84
Methicillin-susceptible S. aureus (631)
Clindamycin 94 2 4
Erythromycin 68 6 26
Trimethoprim-sulfamethoxazole 98 1 1
Tetracycline 85 1 14
Fluoroquinolone 69 21 10
Methicillin-resistant coagulase-negative staphylococci (560)
Clindamycin 67 6 27
Erythromycin 34 1 65
Trimethoprim-sulfamethoxazole 51 2 47
Tetracycline 66 2 32
Fluoroquinolone 39 8 53
Methicillin-susceptible coagulase-negative staphylococci (483)
Clindamycin 92 5 3
Erythromycin 69 4 27
Trimethoprim-sulfamethoxazole 89 1 10
Tetracycline 67 4 29
Fluoroquinolone 79 1 20Prevalence of Inducible Clindamycin Resistance
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importance of the D-zone test to differentiate in-
ducibly clindamycin-resistant isolates of staphylo-
cocci to facilitate the optimal treatment of patients.
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